Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock

Key Points

• Gilead CEO Daniel O’Day sold 15,000 shares at an average price of $169.74, generating approximately $2.55 million. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, leaving him with 551,683 shares.
• Gilead’s latest quarterly results exceeded expectations, with adjusted EPS of $2.55 versus the $2.19 consensus and revenue of $8.30 billion. The company also declared a quarterly dividend of $0.82 per share, equivalent to a 1.9% annualized yield.
• Analyst sentiment remains broadly positive: Gilead has a consensus “Moderate Buy” rating, with 23 Buy ratings and six Holds, while several firms recently raised their price targets to as high as $195.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel O'Day sold 15,000 shares of the company's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $169.74, for a total value of $2,546,100.00. Following the completion of the sale, the chief executive officer owned 551,683 shares in the company, valued at $93,642,672.42. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O'day also recently made the following trade(s):

• On Friday, October 30th, Daniel O'Day sold 15,881 shares of Gilead Sciences stock. The shares were sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00.
• On Tuesday, September 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Stock Down 0.2%

Shares of Gilead Sciences stock traded down $0.35 during mid-day trading on Monday, reaching $170.33. 8,856,542 shares of the stock were exchanged, compared to its average volume of 5,751,038. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a 50-day simple moving average of $151.36 and a 200 day simple moving average of $140.03. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $175.65.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts' consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.47 earnings per share. Analysts expect that Gilead Sciences, Inc. will post -1.03 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences's payout ratio is -103.80%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead said it will present late-breaking clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026 on November 8–11. Updates on HIV therapies, its development pipeline and strategic collaborations could provide catalysts if the results reinforce the company’s leadership in HIV treatment. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
• Positive Sentiment: Analysts have raised several Gilead price targets, including targets of $175, $181, $183, $188, $190 and $200. Separately, an updated fair-value estimate rose from $158.65 to $165.31, reflecting improved views of third-quarter execution, the HIV business and pipeline assets. Gilead Sciences Price Target Raised to $200.00 Gilead Stock Fair Value Edges Higher After Analyst Target Increases
• Positive Sentiment: Gilead continues to receive favorable analyst attention, including a Morgan Stanley Buy rating and inclusion among healthcare stocks described as having Strong Buy ratings and high quantitative scores. Gilead Sciences Receives a Buy from Morgan Stanley
• Neutral Sentiment: Former Gilead U.S. Medical Affairs head Dean Hakanson joined GOA Therapeutics as chief medical officer. The move highlights executive experience gained at Gilead, but it does not directly change Gilead’s operations or financial outlook. Former Gilead Head of U.S. Medical Affairs Joins GOA Therapeutics
• Negative Sentiment: One recent earnings analysis characterized Gilead’s outlook as mixed: revenue guidance was raised, but the EPS outlook worsened. That contrast could limit upside by raising concerns about profitability even as the HIV business remains strong. Gilead Sciences Q3 2026 Earnings Analysis

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth $15,393,785,000. State Street Corp increased its stake in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company's stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the period. Amundi raised its position in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company's stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Gilead Sciences during the second quarter worth $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in shares of Gilead Sciences during the second quarter valued at $918,387,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GILD. Wells Fargo & Company raised their price target on Gilead Sciences from $165.00 to $190.00 and gave the company an "overweight" rating in a report on Friday. UBS Group boosted their price objective on Gilead Sciences from $175.00 to $195.00 and gave the stock a "buy" rating in a research note on Friday. Leerink Partners cut Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Morgan Stanley raised their target price on Gilead Sciences from $163.00 to $183.00 and gave the company an "overweight" rating in a research note on Friday. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $175.00 price target on shares of Gilead Sciences in a report on Monday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $169.74.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.